Vera Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VERA Nasdaq 2836 veratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vera Therapeutics, Inc.

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 9th, 2025 8:05 pm
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch - Apr 9th, 2025 6:51 pm
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN - Apr 3rd, 2025 12:00 pm
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Feb 27th, 2025 1:00 pm
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Feb 26th, 2025 1:25 pm
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor - Jan 13th, 2025 12:00 pm
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 9:05 pm
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - Nov 18th, 2024 1:00 pm
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - Nov 11th, 2024 2:55 pm
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - Nov 11th, 2024 1:00 pm
Vera Therapeutics to Participate at Upcoming Investor Conferences - Nov 8th, 2024 9:05 pm
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Nov 7th, 2024 1:00 pm
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - Oct 30th, 2024 12:21 am
Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Oct 29th, 2024 1:25 pm
Vera Therapeutics Breaks Out On Promising Results For Kidney Drug - Oct 28th, 2024 9:43 pm
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - Oct 28th, 2024 9:37 pm
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - Oct 28th, 2024 2:33 pm
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - Oct 26th, 2024 11:30 pm
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 - Oct 2nd, 2024 10:30 am
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases - Oct 2nd, 2024 10:30 am